## PCT/KR2004/001303

RO/KR 23.05.2005

## **CLAIMS**

1. A skin-care composition containing 20-O- $\beta$ -D-glucopyranosyl-20(S)-protopanaxatriol (ginsenoside F1) and (–)epigallocatechin-3-gallate (EGCG) as active ingredients.

5

15

20

25

- 2. The composition according to Claim 1, wherein said skin-care is obtained by the apoptosis-inhibitory effect of said active ingredients.
- 3. The composition according to Claim 2, wherein said apoptosis is apoptotic cell death induced by low dose of UV irradiation.
  - 4. The composition according to Claims 2 or 3, wherein said apoptosis-inhibitory effect is obtained by regulating the expression of Bcl-2.
  - 5. The composition according to Claim 4, wherein said regulation of Bcl-2 expression is obtained by regulating the expression of Brn-3a.
  - 6. The composition according to any one of Claims 1 to 5, wherein said ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based on the total weight of the composition.
    - 7. The composition according to any one of Claims 1 to 5, wherein said ginsenoside F1 and EGCG are incorporated in a weight ratio of 1:0.1~10.
    - 8. An inhibitor of Rb protein dephosphorylation containing ginsenoside F1

## PCT/KR2004/001303

RO/KR 23.05.2005

and EGCG as active ingredients.

9. An inhibitor of skin damage for preventing cellular damage caused by exposure to ultraviolet rays, containing a combination of low concentrations of ginsenoside F1 and EGCG as an active ingredient.

5

10. An external composition for skin care containing a combination of ginsenoside F1 and EGCG as an active ingredient.